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Alterations of epigenetic marks have an important role in
myeloid malignancies.
1 Mutations have been found in several
epigenetic regulators including ASXL1, DNMT3A, EZH2, IDH1/2
and TET2.
2,3 DNMT3A, IDH1/2 and TET2 are involved in the
regulation of DNA methylation. EZH2 belongs to a complex of
proteins called ‘polycomb repressor complex 2’ (PRC2).
4 ASXL1
is a regulator of PRC1, the other polycomb complex. Several
other proteins belong to the two polycomb complexes; although
alterations of ASXL1
5 and EZH2
6,7 are probably prominent in
myeloid diseases, we suspected that these other PRC compo-
nents might also be involved in some cases.
We searched for mutations in SUZ12, a gene encoding a
PCR2 protein, in 186 whole blood samples from 125
myeloproliferative neoplasms (MPNs), 14 MPNs at the blast-
phase stage and 47 chronic myelomonocytic leukemias
(CMML). The MPNs comprised 33 polycythemia vera (PV) and
4 post-PV myeloﬁbrosis (MF), 51 essential thrombocythemia
(ET) and 9 post-ET MF, 22 primary myeloﬁbrosis, 3 unclassiﬁ-
able and 3 myelodysplastic syndrome/MPN cases. SUZ12 is
located on chromosome arm 17q (Figure 1a) and comprises 16
exons (Figure 1b). We determined the sequence of SUZ12 exons
10 to 16 (the existence of a highly conserved SUZ12
pseudogene prevented easy design of oligonucleotide primers
for SUZ12 exons 1 to 9). In the MPN samples, we also searched
for mutations of JAK2 (exon 14), ASXL1 (exons 12), DNMT3A
(exons 15–23), IDH1 and IDH2 (exon 4), MPL (exon 10) and
TET2 (all exons). Mutations were searched by Sanger DNA
sequencing analysis except for the JAK2 mutation, which was
detected by semi-quantitative PCR. We searched for SUZ12
deletions in 80 of the MPN samples and in the 47 CMML
samples by using array-comparative genomic hybridization
(aCGH) on high-density oligonucleotide microarrays
(Hu-244A, Agilent Technologies, Massy, France), as described
previously.
8 All patients signed an informed consent and the
study was approved by our ethics committee.
We found mutations of SUZ12 in two MPN patients: a PV,
HD-0716 and a blast phase of post-ET MF, HD-1038 (Table 1).
The two mutations were missense and apparently heterozygous
(Figures 1c and d). In the PV case, sequencing of DNA from
buccal swab or CD3-puriﬁed T-cells showed the absence of
variation compared with reference, thus showing that the
mutation was acquired (Figure 1e). The HD-0716 PV case was
JAK2 V617F-positive (the mutated allele burden was 15–30%)
and TET2-mutated. After diagnosis, the patient, a 66-year-old
man, was treated with hydroxyurea. After 2 years of treatment a
blood sample processed and studied as the initial one showed
that the SUZ12 mutation was barely detectable (Figure 1d). The
HD-1038 blast phase of a post-ET MF was diagnosed in an
80-year-old woman. The chronic stage was not available for
study. At the acute stage, the sample was JAK2 V617F-negative
and TET2-mutated (c.3640C4T p.Arg1214Trp), the karyotype
was complex and the aCGH proﬁle showed, among other
alterations, a heterozygous loss of TET2, 7q21-qter spanning
EZH2, 12p12-p13 spanning AEBP2 and 17q11-q21 spanning
NF1 and the other SUZ12 allele (Figure 2). No germline DNA
was available. We did not detect any mutation of ASXL1 in the
two cases, whereas 17 other MPN cases were mutated (Table 1).
We found 2 mutations in DNMT3A,
9 2i nIDH2,1i nMPL
and 15 in TET2.N oSUZ12 mutation was found in the 47
CMML cases.
Deletions of the NF1 gene at 17q11 are frequent in MPNs.
10
By using aCGH we found that the SUZ12 gene, which lies
close to NF1, is often included in these deletions. We found
SUZ12 deletions in three MPNs and in two CMML cases
(Figure 2). This was the case for HD-1038. No aCGH proﬁle
was available for HD-0716. Two other MPN cases (HD-0535
and HD-0728) showed a deletion of a SUZ12 allele but were
not mutated (Table 1); however, as mentioned above, the ﬁrst
nine exons of the gene were not studied. In another MPN case
(HD-0689), the deletion encompassed NF1 but not SUZ12
(Figure 2), suggesting that NF1 was the actual targeted gene of
the deletion.
Our study shows that a mutation can affect a PRC2
component other than EZH2 in few cases of MPN. This
mutation of SUZ12 may substitute for or cooperate with a
mutation of EZH2 to compromise PRC2. This reinforces the
current view that position epigenetic regulators as major players
of leukemogenesis, together with signaling molecules and
transcription factors. SUZ12 mutations are rare but are actually
in the same range as DNMT3A,
9 IDH2 and MPL. Because we
tested only the last exons of the gene our study may have
underestimated the frequency of SUZ12 mutations. Interest-
ingly, in addition to mutations, SUZ12 function could be
affected by gene loss. The 17q11 region encompassing NF1 and
SUZ12 is deleted in MPNs
10 and CMMLs. Our study suggests
that both genes may participate to leukemogenesis, explaining
why the NF1-SUZ12 17q11 region is often lost en bloc. It is also
possible that other genes are involved; we sequenced the exons
of RAB11FIP4, located between the NF1 and SUZ12, in our
series of MPN cases but found no mutation.
PRC2 is the major methyltransferase for H3K27 methylation, a
modiﬁcation of histone H3 that represses gene expression
programs throughout development.
4 Mice with loss of function
mutations in PRC2 components display enhanced activity of
their hematopoietic stem cell/progenitor population and loss of
SUZ12 function in particular enhances hematopoietic stem cell
activity.
11 It remains to be determined whether the mutations we
have identiﬁed lead to a loss of function of the protein. In the
HD-0716 case, the c.1685A4G p.Asn562Ser mutation may
affect the VEFS-box known to be critical for EZH2 interaction,
12
consequently disrupting PRC2 function. In the HD-1038 case,
the deletion of an allele combined with the mutation of the other
allele suggests a two-hit process associated with a tumor
suppressor. Whether SUZ12 mutations are present in other
hematopoietic diseases should be determined. Whether other
PRC2 components, such as AEBP2, EED and JARID2, are
mutated and how they combined with other mutations in
hematopoietic diseases should also be investigated.
Many genes contribute to leukemogenesis through mutations
of their sequence; our study also shows that, beside the
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there may be a number of rarely mutated contributors.
This could render the molecular diagnosis of myeloid
diseases more difﬁcult to establish. Many of these rarely
mutated genes (for example, SUZ12) may affect the
same functions and pathways (for example, polycomb
repression) as the frequently mutated ones (for example,
EZH2).
Figure 1 Mutation of the SUZ12 gene in MPNs. (a) Localization of the SUZ12 gene in chromosomal region 17q11. (b) Representation of the
16 SUZ12 exons. (c) Representation of the 739-amino-acid-long SUZ12 protein with known motifs and domains. Localization of the mutations is
indicated below by arrowheads. (d) Nucleotide sequences for HD-0716 PV case. Sequence of the mutated SUZ12 allele demonstrates change at
the position indicated by an arrow in the sample taken at diagnosis. (e) The mutation was hardly detectable after 2 years of treatment and is absent
from CD3 T-cells and buccal swab samples. The corresponding sequence is shown above the tracks.
Table 1 Mutations and deletions of SUZ12 in patients with myeloproliferative neoplasms
SUZ12
mutation
SUZ12
loss
ASXL1
mutation
ASXL1
loss
DNMT3A
mutation
IDH1/2
mutation
JAK2
mutation
MPL
mutation
TET2
mutation
TET2
loss
Polycythemia vera 1/33 0/7 3/33 0/7 1/33 0/33 32/33 0/33 4/33 0/7
Essential thrombocythemia 0/51 0/19 2/51 0/19 0/51 0/51 32/51 0/51 3/51 0/19
Myeloﬁbrosis 0/35 1/35 8/35 1/35 1/35 0/35 24/35 0/35 4/35 0/35
Other MPN 0/6 0/6 2/6 0/6 0/6 0/6 1/6 0/6 2/6 0/6
Blast phase MPN 1/14
a 2/13
a 2/14 0/13 0/14 2/14 4/14 1/14 2/14
a 2/13
a
Total MPNs 2/139
a 3/80
a 17/139 1/80 2/139 2/139 93/139 1/139 15/139
a 2/80
a
Abbreviation: MPN, myeloproliferative neoplasm.
aHD-1038 sample in common.
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Figure 2 aCGH proﬁle of chromosome 17 in four MPN cases showing loss of the NF1-SUZ12 region. HD-0535 (blue proﬁle), a blast phase
primary myeloﬁbrosis (PMF), HD-0728 (red proﬁle), a PMF and HD-1038 (yellow proﬁle), a blast phase post-ET MF show loss, among other genes,
of NF1 and SUZ12, whereas in HD-0689 (green proﬁle), a PMF, no loss of SUZ12 is observed. Deletion of NF1 but not SUZ12 in HD-0689, and
mutation of SUZ12 in HD-1038 suggest both genes participate in leukemogenesis.
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